Everyday health / TOPIC GUIDE
GLP-1 & metabolic health
Articles, reading companions, and research sources from across The Arising.
Articles on this subject
2026-11-01 · THE ARISING
Remission is a beginning. What helps it last?The RESET diabetes trial, its six-month result, and the next question.
2026-10-31 · THE ARISING
The liver test that could spare a biopsy—but only for the question it answers wellSource: The Lancet, issue dated October 31, 2026; LITMUS prospective multicenter diagnostic-accuracy study, DOI 10.1016/S0140-6736(26)01145-1, PubMed. Evidence: substantial prospective diagnostic…
2026-10-30 · THE ARISING
The glucose sensor crossed a boundary: benefit without insulin therapyOctober 14, 2026 online; October 29 journal issue · Randomized multicenter effectiveness trial; older online result revisited · Primary source
2026-10-30 · THE ARISING
Retatrutide: greater weight loss, more treatment withdrawalsBenefits and tolerability in company-reported trial results. Full peer-reviewed results remain a separate step.
2026-10-29 · THE ARISING
Lilly's Triple-Hormone Drug Retatrutide Beat Ozempic on Blood Sugar and Weight at Its Top DoseAn experimental drug that acts on three hormone signals produced average weight loss of 20% to 21% in a head-to-head diabetes trial. Ozempic produced 9%. The drug, retatrutide, also led to more people…
2026-10-29 · THE ARISING
Coaching Program Linked to Greater Weight Loss in GLP-1 UsersWeight loss on a GLP-1 drug is not only fat loss, and a new study asks whether exercise coaching can change what the body gives up. The fat and muscle figures below come from press coverage, not from the…
2026-10-28 · THE ARISING
GLP-1 cardiovascular protection appears similar across age groupsPublished October 27, 2026 · Systematic synthesis of eight randomized outcome trials · Clinically relevant Primary source: Age-stratified GLP-1RA meta-analysis, PMID 42946897
2026-10-28 · THE ARISING
Normal body weight does not guarantee protection from fatty liver diseasePublished October 28, 2026 · Large retrospective observational analysis · Risk stratification, not causal treatment evidence Primary source: Normal-BMI MASLD study, PMID 42947552
2026-10-28 · THE ARISING
GLP-1 medicines and bone density: what eight trials can tell usA closer look at bone density, weight loss, and the limits of a small evidence base.
2026-10-27 · THE ARISING
Bone Density Fell in GLP-1 Trials With the Most Weight LossIn the two randomized trials where people lost the most weight on a GLP-1 drug, bone mineral density at the spine and hip went down, according to a new systematic review. The authors say the evidence is too…
2026-10-27 · THE ARISING
Whole-Body MRI Study of 14,031 Adults Links Sleep to Belly FatSleeping more may not be the whole story. How efficiently a person sleeps may matter too, according to a new report of company research linking sleep patterns to belly fat and brain size. 14,031 adults
2026-10-27 · THE ARISING
Weight and Blood Sugar Rose Fastest in the First 90 Days After Starting Antipsychotics, Study FindsWeight and blood sugar rose far faster in the first three months after people with severe mental illness started antipsychotic treatment than at any other point the researchers tracked, according to a large…
From the Atlas collection
Original publication dates and review labels are retained.
2026-10-25 · ATLAS READING
Beyond the first prescriptionWhat a study of older adults can—and cannot—tell us about sustained GLP-1 use.
2026-10-25 · ATLAS READING
Where weight and sleep apnea meetA 2024 randomized trial offers context for the newer GLP-1 headlines.